Search Result

Results for "

Amylases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (47) Apoptosis (1) Bacterial (3) Biochemical Assay Reagents (7) Bombesin Receptor (3) CGRP Receptor (1) Cholecystokinin Receptor (5) Cholinesterase (ChE) (4) COX (1) Dipeptidyl Peptidase (4) Endogenous Metabolite (4) Fatty Acid Synthase (FASN) (1) Fungal (1) GLUT (2) Glycosidase (36) HDAC (1) NF-κB (2) P-glycoprotein (1) Phosphatase (2) PPAR (1) Somatostatin Receptor (2) TNF Receptor (2) Tyrosinase (2)
By Research Areas:	Cancer (12) Cardiovascular Disease (1) Endocrinology (2) Infection (1) Inflammation/Immunology (10) Metabolic Disease (67) Neurological Disease (4)

By Targets:

Amylases (47)

Apoptosis (1)

Bacterial (3)

Biochemical Assay Reagents (7)

Bombesin Receptor (3)

CGRP Receptor (1)

Cholecystokinin Receptor (5)

Cholinesterase (ChE) (4)

COX (1)

Dipeptidyl Peptidase (4)

Endogenous Metabolite (4)

Fatty Acid Synthase (FASN) (1)

Fungal (1)

GLUT (2)

Glycosidase (36)

HDAC (1)

NF-κB (2)

P-glycoprotein (1)

Phosphatase (2)

PPAR (1)

Somatostatin Receptor (2)

TNF Receptor (2)

Tyrosinase (2)

By Research Areas:

Cancer (12)

Cardiovascular Disease (1)

Endocrinology (2)

Infection (1)

Inflammation/Immunology (10)

Metabolic Disease (67)

Neurological Disease (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Targets Recommended: Amylases

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0419

Quercimeritrin Quercetin-7-O-β-D-glucopyranoside	Others	Metabolic Disease
Quercimeritrin, isolated from the leaves of Ixeridium dentatum, exhibits significant amylase activity .

HY-P0039

BIM-26226	Bombesin Receptor	Cancer
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC₅₀s in the nanomolar range. BIM-26226 can be used for the research of cancer .

HY-161944

*α-Amylase-IN-8*	Amylases	Metabolic Disease
α-Amylase-IN-8 (compound 44) is an *α-amylase* inhibitor (IC₅₀=58.1 μM). α-Amylase-IN-8 can be used in the research of type 2 diabetes .

HY-P2762

*α-Amylase* from Aspergillus oryzae**	Amylases	Others
α-Amylase from Aspergillus oryzae is an *amylase. α-Amylase* from Aspergillus oryzae can be used for various biochemical studies .

HY-N0419R

Quercimeritrin (Standard)	Others	Metabolic Disease
Quercimeritrin (Standard) is the analytical standard of Quercimeritrin. This product is intended for research and analytical applications. Quercimeritrin, isolated from the leaves of Ixeridium dentatum, exhibits significant amylase activity .

HY-N8326

Maltononaose	Others	Others
Maltononaose is a linear oligosaccharide consisting of 9 glucose units linked by alpha-1, 4-glucoside bonds. Maltononaose is used as a substrate to study the subsites affinity of glucoamylase. Maltononaose can be used to determine the activity of amylase and to optimize the process of starch hydrolysis .

HY-P3112

ICI 216140	Bombesin Receptor	Neurological Disease
ICI 216140 is a GRP/bombesin receptor 2 antagonist with the IC₅₀ of 2 nM. ICI 216140 can reduce Bombesin (HY-P0195)-stimulated pancreatic amylase secretion and attenuates Bombesin (HY-P0195)-stimulated increases in blood pressure .

HY-159491

DPP-4-IN-11	Dipeptidyl Peptidase Glycosidase Amylases	Metabolic Disease
DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC₅₀=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC₅₀=3.02 μM) and *α-amylase* (IC₅₀=3.3 μM) .

HY-161782

*α-Amylase-IN-7*	Amylases	Metabolic Disease
α-Amylase-IN-7 (Compound 6e) is an inhibitor for *α-Amylase* with an IC₅₀ of 40 μM. α-Amylase-IN-7 exhibits potential as an antidiabetic agent .

HY-B2193B

*α-Amylase, Human Pancreas* Amylase, a-Amylase, 1,4-a-D-glucan glucanohydrolase, glycogenase	Others	Others
α-Amylase, Human Pancreas (Amylase, a-Amylase, 1,4-a-D-glucan glucanohydrolase, glycogenase) is a biological material or organic compound that can be used in life science research .

HY-149557

*α-Amylase/α-Glucosidase-IN-5*	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-155241

*α-Amylase/α-Glucosidase-IN-4*	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-146752

*α-Amylase-IN-1*	Others	Others
α-Amylase-IN-1 is a potent *α-amylase* inhibitor with an IC_{50 of 4.46 μM .}

HY-157537

*α-Amylase-IN-5*	Amylases	Metabolic Disease
α-Amylase-IN-5 (compound 3a) is a *α-amylase* inhibitor, with an IC₅₀ of 18.8 mM .

HY-146225

*α-Amylase/α-Glucosidase-IN-2*	Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent *α-amylase* and α-glucosidase dual inhibitor with IC₅₀ values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .

HY-153101

Gal-G2-CNP	Biochemical Assay Reagents	Others
Gal-G2-CNP, a galactopyranosylmaltoside, can be used as substrate for the determination of novel amylase and pancreatic amylase .

HY-147711

*α-Amylase/α-Glucosidase-IN-1*	Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent *α-amylase/α-glucosidase* inhibitor with IC₅₀s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .

HY-B2192

*Amylase*	Amylases	Metabolic Disease Cancer
Amylase is an enzyme produced by pancreas and salivary glands, catalyzing the hydrolysis of starch into sugars. Amylase are broadly classified into α, β, and γ subtypes .

HY-P2770

*β-Amylase, Bacilus subtilis*	Others	Others
β-Amylase, Bacilus subtilis has abundant starch degrading activities. β-Amylase can be used for various biochemical studies .

HY-149973

*α-Amylase-IN-4*	Others	Metabolic Disease
α-Amylase-IN-4 (Compd 10y) show maximum inhibition of amylase activity with IC₅₀ value 17.83 ± 0.14 μg/mL .

HY-162169

*α-Amylase/α-Glucosidase-IN-8*	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of *α-amylase* and α-glucosidase, with IC₅₀s of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC₅₀ = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes .

HY-162390

*α-Amylase/α-Glucosidase-IN-11*	Amylases Glycosidase	Endocrinology
α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits *α-amylase* (IC₅₀ = 30.39 μM) and α-glucosidase (IC₅₀ = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier .

HY-161469

*α-Amylase/α-Glucosidase-IN-13*	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-13 (Compound 5d) is a dual inhibitor of *α-Amylase/α-Glucosidase* that can be used for diabetes research .

HY-149313

*α‑Amylase-IN-1*	Amylases	Metabolic Disease
α Amylase-IN-1 (Compound 11) is an *α-Amylase* inhibitor with an IC₅₀ value of 0.5509 μM. α Amylase-IN-1 has antioxidant activity with an IC₅₀ value of 53.49 μM for scavenging DPPH free radicals. IC₅₀ can be used in the study of diabetes and oxidative stress-related diseases.

HY-154972

*α-Amylase/α-Glucosidase-IN-3*	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an *α-Amylase/α-Glucosidase* dual inhibitor, with IC₅₀s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus .

HY-156380

*α-Amylase/α-Glucosidase-IN-6*	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of *α-amylase* and α-glucosidase, with IC₅₀s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .

HY-162673

*α-Amylase/α-Glucosidase-IN-16*	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-16 (compound 15) is a potent dual inhibitor of *α-amylase* and α-Glucosidase with IC₅₀ values of 0.8 and 1.2 μM, respectively. α-Amylase/α-Glucosidase-IN-16 can be used in the study of diabetes mellitus (DM) .

HY-149008

*α-Amylase-IN-3*	Amylases	Metabolic Disease Cancer
α-Amylase-IN-3 (Compound 4) is a none-competitive type of *α-Amylase* inhibitor with an IC₅₀ value of 18.04 μM, which also has radical scavenging activities (DPPH and ABTS) with IC₅₀ values of 16.04 μM (DPPH) and 16.99 μM (ABTS), respectively. α-Amylase-IN-3 has good protein–ligand interactions profile against α-Amylase. α-Amylase-IN-3 may have pharmacological activities such as anti-oxidative, anti-inflammatory inhibitory, which is helpful for the development of diabetes and oxidative stress associated disease .

HY-168598

*α-Amylase-IN-9*	Amylases	Metabolic Disease
α-Amylase-IN-9 (Compound 1i) is an inhibitor of *α-Amylase* with an IC₅₀ value of 14.64 μM, which can be used in diabetes research .

HY-162036

*α-Amylase/α-Glucosidase-IN-7*	Glycosidase Amylases Cholinesterase (ChE)	Neurological Disease Metabolic Disease
α-Amylase/α-Glucosidase-IN-7 (Compound 3f) is a competitive α-glucosidase and *α-amylase* enzyme inhibitor with IC₅₀ values of 18.52 and 20.25 µM, respectively. α-Amylase/α-Glucosidase-IN-7 can also effectively inhibit AChE and BChE, with IC₅₀ values of 9.25 and 10.06 µM respectively. α-Amylase/α-Glucosidase-IN-7 can be used in diabetes and Alzheimer’s research .

HY-135530

Chinese gallotannin	Amylases	Metabolic Disease
Chinese gallotannin is a non-specific promiscuous *α-amylase* inhibitor with a K_i of 0.82 μg/mL for human salivary α-amylase. Chinese gallotannin can be used for the research of diabetes .

HY-162634

*α-Amylase/α-Glucosidase-IN-15*	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-15 (compound 6C) is an oral bioactive inhibitor of α-Glucosidase and *α-amylase, with the IC₅₀*s of 21 μM and 61 μM, respectively .

HY-112835

Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside pNP-G7	Amylases	Others
Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside (pNP-G7) is the substrate of α-amylase. Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside can be used to measure a-amylase activity .

HY-N7729

Sekikaic acid	Amylases Glycosidase	Metabolic Disease
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .

HY-161355

*α-Amylase/α-Glucosidase-IN-9*	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both *α-amylase* (IC₅₀ = 16.4 μM) and α-glucosidase (IC₅₀ = 31.6 μM) enzymes .

HY-162373

*α-Amylase/α-Glucosidase-IN-10*	Amylases Glycosidase P-glycoprotein	Metabolic Disease
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC₅₀: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .

HY-162635

*α-Amylase/α-Glucosidase-IN-14*	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-14 (compound 6E) is an oral bioactive inhibitor of *α-amylase* and α-glucosidase, with the IC₅₀s of 45.53 μM and 27.73 μM, respectively .

HY-163439

*α-Amylase/α-Glucosidase-IN-12*	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC₅₀ of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research .

HY-B2192A

Diastase, Aspergillus oryzae Maltin	Biochemical Assay Reagents	Others
Diastase is an amylase from Aspergillus oryzae that hydrolyzes starch into sugars .

HY-137228

4-Nitrophenylmaltohexaoside	Biochemical Assay Reagents	Others
4-Nitrophenylmaltohexaoside is a chromogenic substrate targeting α-amylase.

HY-116576

LY219057	Cholecystokinin Receptor	Metabolic Disease
LY219057 is a potent antagonist of cholecystokinin octapeptide (CCK-8), with the ID₅₀ of 287.5 nM .

HY-133718

Acarviosin (S)-Acarviosin	Amylases	Others
Acarviosin, a pseudodisaccharide moiety, is a part of the potent inhibitor of α-amylase .

HY-P2968

Bacterial α-Amylase	Amylases	Others
Bacterial α-Amylase catalyses the hydrolysis of internal α-1,4-glycosidic linkages in starch in low molecular weight products, such glucose, maltose and maltotriose units. Bacterial α-Amylase is often used in biochemical studies .

HY-N2464

Maltotetraose Amylotetraose; Fujioligo 450; α-1,4-Tetraglucose	TNF Receptor Endogenous Metabolite Bacterial	Metabolic Disease
Maltotetraose can be used as a substrate for the enzyme-coupled determination of amylase activity in biological fluids.

HY-118194

A-65186	Others	Others
A-65186 is a CCK-A receptor antagonist with the activity of inhibiting CCK8-induced amylase secretion. A-65186 has high binding affinity for pancreatic CCK-A receptors, is more than 500 times more selective for CCK-A receptors than for CCK-B receptors, and can inhibit CCK8-induced amylase secretion.

HY-132179

Fucoidan 2 Publications Verification	Glycosidase	Cardiovascular Disease Metabolic Disease Cancer
Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities .

HY-N12263

3,5,6,7,8,4'-Hexamethoxyflavone	Amylases	Metabolic Disease
3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of *α-Amylase* with the inhibitory activity of 28.3% at 500 μM .

HY-N11844

Quercetin 3-(6″-caffeoylsophoroside)	Amylases	Metabolic Disease
Quercetin 3-(6″-caffeoylsophoroside) is an orally active *α-amylase* inhibitor, with an IC₅₀ of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .

HY-146981

α-Glucosidase-IN-3	Glycosidase	Inflammation/Immunology
α-Glucosidase-IN-3 is an oleanolic acid (OA) oxime ester derivativ eagainst α-glucosidase(IC₅₀=0.35 µM) and α-amylase.

HY-E70183

Lysosomal α-Glucosidase EC:3.2.1.20; GAA	Biochemical Assay Reagents	Others
Lysosomal α-Glucosidase (EC:3.2.1.20) is a γ-amylase with specificity for glycogen and several natural and synthetic oligoglucosides .

Cat. No.	Product Name	Type

HY-W009694

3,5-Dinitrosalicylic acid	Indicators
3,5-Dinitrosalicylic acid the derivative of salicylic acid. 3,5-Dinitrosalicylic acid is used in the α-amylase assay, carbohydrase assay, and for the colorimetric determination of reducing substances .

HY-W005598

2-Hydroxyquinoline	Biochemical Assay Reagents
2-Hydroxyquinoline is a potent α-glucosidase inhibitor with IC₅₀ values of 64.4, 130.5 µg/mL for α-glucosidase and α-amylase, respectively. 2-Hydroxyquinoline has the potential for the research of diabetes .

HY-153102

G3-CNP	Enzyme Substrates
G3-CNP is an α-amylase substrate. The absorbance of G3-CNP cleavage product 2-chloro-4-nitrophenol is measured at 405 nm, which can be used to detect enzyme activity .

HY-153101

Gal-G2-CNP	Enzyme Substrates
Gal-G2-CNP, a galactopyranosylmaltoside, can be used as substrate for the determination of novel amylase and pancreatic amylase .

HY-137228

4-Nitrophenylmaltohexaoside	Cell Assay Reagents
4-Nitrophenylmaltohexaoside is a chromogenic substrate targeting α-amylase.

HY-E70183

Lysosomal α-Glucosidase EC:3.2.1.20; GAA	Enzyme Substrates
Lysosomal α-Glucosidase (EC:3.2.1.20) is a γ-amylase with specificity for glycogen and several natural and synthetic oligoglucosides .

HY-137785

2-Chloro-4-nitrophenyl-β-D-maltotrioside	Cell Assay Reagents
2-Chloro-4-nitrophenyl-β-D-maltotrioside is a chromogenic substrate used in bioluminescent and fluorescent assays to detect α-amylase.

Cat. No.	Product Name	Target	Research Area

HY-P0039

BIM-26226	Bombesin Receptor	Cancer
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC₅₀s in the nanomolar range. BIM-26226 can be used for the research of cancer .

HY-P3377

Rimtoregtide	Peptides	Inflammation/Immunology
Rimtoregtide is a polypeptide compound which significantly reduces the increase in the levels of amylase and lipase in the blood caused by acute pancreatitis. Rimtoregtide has the potential for the research of pancreatitis and acute pancreatitis (extracted from patent WO2018205233A1).

HY-P3462A

Cagrilintide acetate	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-P1096

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

HY-P3899A

[Nle8] Somatostatin (1-28) (TFA)	Somatostatin Receptor	Metabolic Disease
[Nle8] Somatostatin (1-28) TFA is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) TFA increases the amylase release.[Nle8] Somatostatin (1-28) TFA increases the cyclic AMP in pancreatic acini .

HY-P1133

Galanin (2-29) (rat) Rat galanin(2-29)	Peptides	Others
Galanin (2-29) (rat) inhibits rat pancreatic protein and CCK-8-stimulated amylase secretion. Galanin (2-29) (rat) is an GAL2R agonist (K_i: 3.5 nM) .

HY-P3112

ICI 216140	Bombesin Receptor	Neurological Disease
ICI 216140 is a GRP/bombesin receptor 2 antagonist with the IC₅₀ of 2 nM. ICI 216140 can reduce Bombesin (HY-P0195)-stimulated pancreatic amylase secretion and attenuates Bombesin (HY-P0195)-stimulated increases in blood pressure .

HY-P3899

[Nle8] Somatostatin (1-28)	Somatostatin Receptor	Metabolic Disease
[Nle8] Somatostatin (1-28) is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) increases the amylase release.[Nle8] Somatostatin (1-28) increases the cyclic AMP in pancreatic acini .

HY-103282

[D-Phe12]-Bombesin	Bombesin Receptor	Others
[D-Phe12]-Bombesin is a derivative of Bombesin (HY-P0195) and an antagonist for bombesin receptor with K_i of 4.7 μM. [D-Phe12]-Bombesin inhibits the Bombesin (HY-P0195)-induced amylase release, with IC₅₀ of 4 μM .

HY-P2055

A-57696	Peptides	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks